(Q37474385)

English

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

scientific article published on 05 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

breast neoplasm

1 reference

based on heuristic

inferred from title

Steven T. Piantadosi

14

object named as

Steven Piantadosi

1 reference

Europe PubMed Central

20 August 2017

11

object named as

Vered Stearns

1 reference

Europe PubMed Central

20 August 2017

Elizabeth Jaffee

17

object named as

Elizabeth M Jaffee

1 reference

Europe PubMed Central

20 August 2017

author name string

Leisha A Emens

1

1 reference

Europe PubMed Central

20 August 2017

Justin M Asquith

2

1 reference

Europe PubMed Central

20 August 2017

James M Leatherman

3

1 reference

Europe PubMed Central

20 August 2017

Barry J Kobrin

4

1 reference

Europe PubMed Central

20 August 2017

Silvia Petrik

5

1 reference

Europe PubMed Central

20 August 2017

Marina Laiko

6

1 reference

Europe PubMed Central

20 August 2017

Joy Levi

7

1 reference

Europe PubMed Central

20 August 2017

Maithili M Daphtary

8

1 reference

Europe PubMed Central

20 August 2017

Barbara Biedrzycki

9

1 reference

Europe PubMed Central

20 August 2017

Antonio C Wolff

10

1 reference

Europe PubMed Central

20 August 2017

Mary L Disis

12

1 reference

Europe PubMed Central

20 August 2017

Xiaobu Ye

13

1 reference

Europe PubMed Central

20 August 2017

John H Fetting

15

1 reference

Europe PubMed Central

20 August 2017

Nancy E Davidson

16

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

5 October 2009

1 reference

Europe PubMed Central

20 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

20 August 2017

27

1 reference

Europe PubMed Central

20 August 2017

5911-5918

1 reference

Europe PubMed Central

20 August 2017

35

1 reference

Europe PubMed Central

20 August 2017

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Toward a breast cancer vaccine: work in progress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Cancer vaccines: an old idea comes of age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

23 August 2017

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

14 September 2017

Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

14 September 2017

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

14 September 2017

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

14 September 2017

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

14 September 2017

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

26 June 2018

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

26 June 2018

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

26 June 2018

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 September 2018

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 October 2018

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 October 2018

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2793039

2 October 2018

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced immune priming with spatial distribution of paracrine cytokine vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.23.3494

1 reference

Europe PubMed Central

20 August 2017

release_zxdxaq54j5aj3lanrhuo6j2rvy

1 reference

https://api.fatcat.wiki/v0/release/zxdxaq54j5aj3lanrhuo6j2rvy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37474385&oldid=2089063904"